) were compared with recently derived screening biomonitoring equivalent (BE) values . A BE is defined as the estimated concentration or range of concentrations of a chemical or its metabolites in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guidance value. Blood concentrations of VOCs from the NHANES data set were compared with predicted screening BE values based upon a hazard quotient (HQ) for individual chemicals, and a hazard index (HI) approach for combined exposures. HI values for detected chemicals were generally at or below a value of 1, suggesting that the potential for deleterious effects is low. However, smoking was an important determinant of HI and HQ values. Detected levels of benzene in non-smokers were within the range of BE values corresponding to a 1 Â 10 À6 -1 Â 10 À4 range for upper-bound cancer risk; in smokers, levels of benzene were at the upper end of or exceeded this range. For VOCs that were not detected in the NHANES sampling, analytical detection limits were generally sufficiently sensitive to detect concentrations consistent with existing non-cancer and cancer risk-based exposure guidance values. Interpretations of measured blood concentrations of VOCs must be made with caution due to the substantial within-individual, within-day fluctuations in levels expected due to the rapid elimination of VOCs.
Introduction
The National Health and Nutrition Examination Survey (NHANES) generates US population-representative biomonitoring data for many chemicals including volatile organic chemicals (VOCs) in blood (CDC, 2009) . These biomonitoring data have been considered by some to be the gold standard for exposure assessment (Sexton et al., 2005) , and provide valuable information to scientists, physicians, and health officials. The CDC lists a number of uses for the biomonitoring data:
to determine which chemicals get into the US population and at what concentrations; to establish baseline values that can be used to determine whether a person or group has an unusually high exposure; to assess the effectiveness of public health efforts to reduce exposure of the Americans to specific chemicals; to determine whether exposure levels are higher in specific subpopulations, such as minorities and children; to evaluate trends in levels of exposure over time; to set priorities for research on human health effects; and to determine the prevalence of people with levels above established health-based levels (CDC, 2009 ).
The last use requires availability of the ''established healthbased levels.'' Development of epidemiologically based, scientifically sound human health screening criteria for clinical use is a resource-and time-intensive effort that requires a biomarker for an established health endpoint to be (1) reliable, reproducible across multiple laboratories, sensitive and specific, and (2) clearly and consistently associated with a clinical condition or disease (NRC, 2010) . Scientific evidence demonstrating a cause and effect of relationship of the kind needed to be a clinical biomarker, is lacking for exposures to most environmental chemicals.
Until recently, health-based screening values for biomonitoring data were only available for a small number of chemicals (e.g., blood lead levels greater than or equal to 10 micrograms per deciliter (Z10 mg/dl)). As emphasized by the CDC, ''[T] he presence of a chemical does not imply disease. The levels or concentrations of the chemical are more important determinants of the relation to disease, when established in appropriate research studies, than the detection or presence of a chemical' ' (CDC, 2005) . Thus, without quantitative criteria for a screening-level evaluation of biomonitoring data in a risk assessment context, public health professionals cannot assess the potential level of risk associated with specific biomonitoring levels, nor the relative risks posed by different chemicals.
As an interim approach, the development of biomonitoring equivalents (BEs) has been proposed, and guidelines for their derivation and communication have been developed (Hays et al., 2007 LaKind et al., 2008) . A BE is defined as an estimate of the concentration or range of the concentrations of a chemical or its metabolites in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guidance value such as a reference dose (RfD) developed by USEPA, a minimal risk level (MRL) developed by ATSDR, or tolerable daily intake (TDI) developed by the Health Canada. Existing chemical-specific pharmacokinetic data are used to estimate biomarker concentrations that are consistent with the point of departure used in the derivation of an exposure guidance value (such as the RfD, MRL, or TDI), and with the exposure guidance value itself. BEs can be estimated using available human or animal pharmacokinetic data (Hays and colleagues, 2008) , and have been derived for numerous compounds including acrylamide, cadmium, 2,4-dichlorophenoxyacetic acid, toluene, and others (reviewed in Hays and Aylward, 2009 and available at http://www.biomonitor ingequivalents.net). The BE values are intended to be used as screening tools to allow the evaluation of biomonitoring data in a risk assessment context. As such, BE values can be used to examine biomonitoring data to assess which chemicals have large, small, or no margins of exposure compared with the existing exposure guidance values. BE values are only as robust as the underlying exposure guidance values and pharmacokinetic data used to derive the values. The BE values are not intended to be diagnostic for potential health effects in humans, either individually or among a population.
The BEs can be used similar to the way the underlying RfD, MRL, or TDI values are used. For example, to evaluate potential risks in a population exposed to a contaminant in drinking water, the risk assessors first estimate the intake (exposure or dose) in the population of concern (in mg/kg/day) and then compare that estimate with the RfD (mg/kg/day). USEPA defines the oral RfD as, ''An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. It can be derived from a NOAEL, LOAEL, or benchmark dose, with uncertainty factors generally applied to reflect limitations of the data used.' ' (USEPA, 2002) . Therefore, if the dose (exposure level) falls below the RfD, there is little concern for any adverse health effects in the population. The BE reflects a conversion of toxicity values to a concentration (mg/l) in the whole blood, serum, urine, or other biological matrix as appropriate, corresponding to a daily exposure to the substance at an intake equal to the RfD. Then, in a manner analogous to health risk estimation based on intakes, human biomonitoring-measured results can be compared with the BE to assess potential health hazards/risks.
The BE values were previously derived for four trihalomethane (THM) compounds found as drinking water disinfection byproducts , and applied to evaluation NHANES 2003 NHANES -2004 data for the THMs in the blood (LaKind et al., 2009 ). However, screening values based on human clinical data are generally not available for interpreting the health risk significance of the levels of the other VOC compounds included in NHANES. Previously, steady-state solutions to a generic VOC physiologically based pharmacokinetic (PBPK) model were used to estimate steady-state concentrations of VOCs in blood consistent with existing cancer and non-cancer reference values (RfDs, RfCs, TDIs, and cancer risk-specific doses) . These screening-level BEs are consistent in concept with the BEs, but unlike comprehensive BEs, detailed consideration of the chemical-specific mode of action data and relevance to screening-level derivation was not conducted in the analysis. The screening BE values can provide a basis for an initial risk-based examination of the data on concentrations of VOCs in the blood collected in the NHANES program.
This analysis presents a comparison of the available biomonitoring data for VOCs in the blood from NHANES (CDC, 2009) with these recently derived screening BE values . For VOCs detected in the NHANES data set, blood levels were compared with the screening BE values. This comparison allows for a prioritization among the measured VOCs for a possible further risk assessment followup . For those VOCs that were not detected in the NHANES sampling, the analytical detection limits were compared with the screening BE values to assess whether the data are sufficiently sensitive to provide information that is relevant in the context of the existing risk assessments. Issues relevant to the interpretation of measured blood concentrations of these transient, rapidly eliminated compounds (half-lives of elimination of less than an hour to a few hours) and issues related to exposures to multiple VOCs are also discussed.
Materials and methods

Biomonitoring Data
Biomonitoring data for 28 VOCs in blood were obtained from CDC 's 2003 's -2004 's survey period (CDC, 2009 , which includes data from 1367 individuals. VOCs were measured in the blood using isotope dilution, solid-phase microextraction, gas chromatography, and mass spectrometry (Blount et al., 2006; Chambers et al., 2011) . Laboratory measurements underwent extensive quality control and quality assurance review, including tolerance limits for operational parameters, the measurement of quality control samples in each analytical run to detect unacceptable performance in accuracy or precision, and verification of traceable calibration materials (CDC, 2009) . For the purposes of comparing results with the screening BE values, data for o-, m-, and p-xylenes were summed to determine the total xylene concentration for each individual, as the existing exposure guidance values do not differentiate amongst the xylene isomers. In addition, because cigarette smoking can influence blood levels for a number of chemicals (e.g., benzene, toluene, ethylbenzene, styrene, and xylenes), the concentrations of these chemicals in the blood were characterized separately based upon the smoking status as determined by the presence of detectable levels of 2,5-dimethylfuran (DL ¼ 0.012 mg/l), a component of cigarette smoke, in blood (Ashley et al., 1996; Chambers et al., 2011) .
Summary statistics for central tendency values (geometric mean (GM) and its 95% confidence interval) and range (5th and 95th percentiles) are provided (Table 1 ). In calculating the summary statistics, samples with non-detects were imputed with a value equal to the detection limit divided by the square root of 2. Although CDC does not typically calculate and report GMs for chemicals with a detection frequency less than 60% (CDC, 2009), it was assumed here that VOCs present in at least 5% of the samples could theoretically be present in the population at levels below the detection limit. Thus, GM values for VOCs detected in less than 60% but greater than 5% of the samples were calculated here using this imputation, to permit a comparison with the BE values. This approach results in some additional uncertainty in the calculated HQs for these compounds.
For VOCs detected in fewer than 5% of samples, summary statistics were not calculated here. It was assumed that exposures to VOCs detected in fewer than 5% of the samples are isolated in nature, and therefore comparison of their intermittent concentrations to steady-state screening BE values is inappropriate. However, detection limits for these chemicals were included in the evaluation (see section Comparisons) to assess whether the analytical sensitivity of the NHANES sampling program was sufficient to provide meaningful information in the context of current risk assessments for these compounds.
Biomonitoring Equivalents
Screening BE values for VOCs were derived previously . To support BE derivation for VOCs, two types of information were required: (1) existing exposure guidance values such as RfDs, RfCs, TDIs, MRLs, cancer slope factors, and so on; and (2) key pharmacokinetic model parameters . Using steady-state solutions to a generic VOC PBPK model, chemical-specific steady-state venous blood concentrations were estimated across chemicals consistent with the existing exposure guidance values. These solutions permit an algebraic approach to calculate the steady-state blood concentrations associated with the steady-state exposure conditions for VOC compounds, using a limited subset of chemical-specific parameters, without necessitating the implementation of a full PBPK model for each chemical. Up to four screening BE values (corresponding to oral non-cancer, inhalation non-cancer, oral cancer, and inhalation cancer assessments) were derived for each VOC, depending upon the availability of appropriate toxicity values and whether a chemical had been identified as a carcinogen by a regulatory agency. No independent derivations of exposure reference values were carried out.
The chemical-specific blood concentration screening values for the VOCs of interest based on non-cancer reference values for both the oral and inhalation exposure range 0.01-100 mg/l (Table 2) , and the blood concentrations associated with chronic exposure at cancer risk-specific doses at the 1 Â 10 À5 risk level ranged 0.00009-0.06 mg/l (Table 2) . BE values were not derived for 1,3-dichlorobenzene or 2,5-dimethylfuran due to the lack of available exposure guidance values from a regulatory agency. The distribution of modeled steady-state blood concentrations associated with unit exposure levels across the VOCs, may provide a basis for estimating blood concentration screening values for VOCs that lack chemical-specific pharmacokinetic data, as was proposed for 1,2-dichloropropane, 1,2-dibromo-3-chloropropane, chlorobenzene, nitrobenzene, and 1,4-dichlorobenzene .
Comparisons
Biomonitoring data provide an internal dose measure that reflects absorbed compound from multiple routes of exposure (oral, inhalation, and dermal) . Due to the inherent volatile nature of the VOCs of interest in this work, it was expected that inhalation would be the predominant route of exposure. However, uncertainty remains with respect to the degree to which other routes of exposures (e.g., oral or dermal exposures in drinking water) contribute. To address this uncertainty, the biomonitoring data were compared with the BE values for both the inhalation and oral exposures. Toxicity values for dermal exposure are generally not available, and therefore corresponding screening BE values were not derived. Due to the transient nature of VOCs in blood, the screening BE values are best applied to assess central tendency values for the biomonitoring data for the population (e.g., GM) (discussed in Aylward et al., 2010) . To facilitate comparisons, hazard quotient (HQ) values for noncancer endpoints (USEPA, 1989) were calculated for each chemical and exposure route-specific screening BE value using the GM concentration for detected VOCs (detection frequency greater than 5%), and the detection limit for all VOCs using the following equation:
Where, HQ ¼ hazard quotient; GM ¼ geometric mean (Table 1) ; DL ¼ detection limit (Table 1) ; and BE nc ¼ screening BE value for non-cancer endpoints following inhalation or oral exposure (Table 2) .
A hazard index (HI) approach was adopted to examine the potential hazards associated with combined exposures to VOCs. A detailed examination of the mode of action for each chemical was not conducted. Instead, chemicals were grouped by the target organ system under a worst-case assumption of a common mode of action (USEPA, 2000 (USEPA, , 2007 . This approach is expected to be a highly conservative, screening-level method for assessing the potential impacts of the low-level exposure to multiple chemicals, as different toxicity endpoints in the same target organ system would not Smokers and non-smokers were designated by the presence or absence of detectable levels of 2,5-dimethylfuran (Ashley et al., 1996) , and breakouts by smoking status were presented only for those compounds previously evaluated by Chambers et al., (2011) Screening BE evaluation for VOCs Kirman et al.
necessarily result in additive or cumulative toxicity. Within the context of the IPCS conceptual framework for the combined exposures to multiple chemicals, this corresponds to a conservative (health protective) ''Tier 0'' analysis that is ''yconsidered to be conservative and protective, given the common underlying premise of being based on critical effects occurring at lowest dose.' ' (WHO, 2009) . HI values were calculated for each target organ system (i.e., the bases for the key toxicity values listed in Table 2 
Results
Of the 28 VOCs analyzed in NHANES, 15 chemicals were detected (Table 1) . Five VOCs were frequently detected (460% of samples for smokers and non-smokers combined: benzene, ethylbenzene, toluene, xylenes, and methyl-tertbutylether). Four VOCs were moderately detected (5-60% of samples for smokers and non-smokers combined: 1,4-dichlorobenzene, 2,5-dimethylfuran, styrene, and tetrachloroethylene). Six VOCs were infrequently detected (o5% of the samples: carbon tetrachloride, dibromomethane, dichloromethane, 1,1,2,2-tetrachloroethane, 1,1,1-trichloroethane, and trichloroethylene).
Based upon a comparison of the GM values, blood levels for benzene, ethylbenzene, styrene, toluene, and xylene were generally higher in the smokers than in the non-smokers by approximately two-to six-fold, resulting in higher HQ values in smokers (Figure 1a and b) . For non-smokers, HQ values for all detected chemicals were below 1. For smokers, HQ values for oral and inhalation exposures to benzene were approximately equal to 1. The HQ values for xylenes in smokers approached a value of 1 for the inhalation route, but for all other chemicals were below 1.
A target organ system-specific HI value of approximately 1 was calculated for the blood system effects in smokers (inhalation exposure) (Table 3) , which was almost entirely attributable to benzene. An HI value of 0.9 was estimated for the neurological system in smokers, based principally on the contribution of the HQ for xylene. The HI values for all the other target organ systems in both smokers and non-smokers were below a value of 1 (Table 3) .
Benzene was the only frequently detected VOC in the NHANES data set for which a cancer-based screening BE value was derived in Aylward et al., (2010) to allow a comparison. GM blood levels for benzene were generally higher in the smokers (0.136 mg/l) than in the non-smokers (0.024 mg/l) (see Table 1 ). The GM for non-smokers falls within the range of BE values that correspond to an upperbound risk estimate of 1 Â 10 À6 -1 Â 10 À4 , while the GM for smokers slightly exceeds this range. The GM for benzene in the non-smokers is driven by the imputed value for nondetected concentrations, as detection frequency and levels were low in non-smokers (see Table 1 ). No cancer-based screening BE values were available for comparison for blood level data for the other frequently or moderately detected VOCs . Analytical detection limits for the VOCs in the 2003-2004 NHANES data set are generally lower than the non-cancer screening BE values for both the routes of exposure, with the exception of nitrobenzene (inhalation and oral exposures) and 1,2-dibromo-3-chloropropane (inhalation exposure) (Figure 2a and b) . Detection limits for VOCs in blood are compared with the cancer-based BE values in 
Discussion
In this assessment, biomonitoring data for VOCs in the blood from NHANES (CDC, 2009) were compared with the screening BE values for non-cancer and cancer endpoints ). An implicit assumption in this evaluation is that the detected concentrations in blood represent chronic blood concentrations in individuals (the basis of the screening BE values). This is likely to be a highly conservative assumption for any given chemical and individual, given the biologically transient nature of these compounds (Sexton et al., 2005) . However, this at least provides a basis for examination of the levels of detected blood concentrations relative to levels of interest in a risk assessment context across the different chemicals in the NHANES data set. For detected chemicals, using a health protective screening approach, HQ and HI values were generally at or below a value of 1, suggesting that the potential for deleterious noncancer effects is low. However, VOCs associated with cigarette smoke were the most frequently detected VOC compounds in both smokers and non-smokers, and the calculated HQ and HI values were higher in the smokers than in the non-smokers. With respect to cancer risk-based screening BE values, the GM of benzene concentrations detected in the blood of smokers was slightly higher than the range of screening BE values associated with a 1 Â 10 À6 -1 Â 10 À4 cancer risk. However, if the screening BE had been calculated using the lower end of the range of cancer potency estimates derived by USEPA for benzene (Table 2) , the GM value in smokers would fall below the 1 Â 10 À4 cancer risk level. Benzene exposure has been associated with the increased risk of acute myeloid leukemia in occupationally exposed populations. Occupational cohort data on total leukemia are the basis of the cancer risk assessment for benzene from the USEPA (which served as the basis for the derivation of the screening BE values used here). The estimated lifetime risk of developing acute myeloid leukemia for an individual born today is approximately 4 Â 10 À3 (SEER, 2011). Thus, the theoretical cancer risks associated with the observed concentrations of benzene in the blood in NHANES data set in smokers (based on the USEPA cancer slope factor and corresponding screening BE values) fall approximately an order of magnitude below this level of lifetime risk. For smokers, the potential risk of leukemia due to benzene is likely to be small compared with the other cancer risks (e.g., lung cancer) associated with smoking in general. (Table 1 ). *GM values used to calculate the HQ were heavily influenced by the large proportion (440%) of non-detected values (evaluated using DL/O2).
The cancer risk-specific doses (RSDs), from which the cancer-based BE values were derived, are estimates of the lifetime average daily exposure associated with a given cancer risk level for a chemical. Screening BE values for cancer RSDs provide an estimate of the steady-state blood concentrations that would result from chronic exposure at those risk-specific doses. However, it isn't possible to draw conclusions regarding the lifetime cancer risks based on spot samples of transient compounds in blood of individuals.
Blood concentrations would have to be maintained chronically for a lifetime at those levels to result in the corresponding cancer risk levels. Furthermore, those riskspecific doses are based on upper-bound assessments of cancer potency; the true cancer potency for a given chemical is likely to be lower and may be zero, so while comparison of the measured blood concentrations with the cancer RSDbased screening BE values provides some information that is useful in comparing and prioritizing across chemicals, it cannot be used to estimate individual cancer risks, particularly not for biologically transient compounds such as benzene and other VOCs.
Analytical detection limits for VOCs in blood are generally sufficient to detect the blood concentrations of these compounds consistent with the existing non-cancer chronic exposure reference values, and with the risk-specific exposure levels in the range of 1 Â 10 À6 -1 Â 10 À4 cancer risk. Thus, the absence of any detectable levels of these compounds (with the few exceptions noted above in the results) should be interpreted in the context of existing risk assessments, as providing clear information that exposures in the general population as reflected in the NHANES sampling were below the levels of concern based on the current risk assessments. The analytical detection limits for 1,2-dibromo-3-chloropropane, 1,2-dichloropropane, and nitrobenzene in the NHANES program are above the risk-specific screening BE values for the 1 Â 10 À6 -1 Â 10 À4 cancer risk range, and above the non-cancer screening BE values for 1,2-dibromo-3-chloropropane and nitrobenzene. However, this does not indicate the presence of risk to the population, as actual concentrations of the VOCs in blood, if at all present, may be considerably lower than the detection limits. If further assessment of potential exposure levels is required for nondetected compounds, other approaches may be useful. These could include: (1) conducting a targeted study that collects larger sample volumes than are available through NHANES; (2) development of refined analytical methods allowing greater sensitivity; (3) pooling of samples across individuals to obtain a higher sample volume for a population estimate (however, estimates of variation would no longer be possible); and (4) exposure pathway characterization to determine if the exposure pathways of potential concern as identified by the risk assessments (oral exposure for 1,2-dibromo-3-chloropropane and 1,2-dichloropropane; inhalation exposure for nitrobenzene) are valid.
Inter-individual variation in the blood VOC levels appears to be moderate for chemicals that were frequently detected, with the 95th percentile values approximately two-to sevenfold higher than their corresponding GM values, reflecting skewness typically observed in lognormally distributed data sets (Table 1) . Greater inter-individual variation (95th percentiles more than 10-fold above the limit of detection) was noted for infrequently detected chemicals, which may reflect detection of isolated exposures or special subpopulations rather than the upper tails of a continuous population distribution of levels. These data suggest that for some individuals, HQ and HI values may be higher than those calculated using the GM values. However, the screening BE values derived herein correspond to predicted chronic steady-state blood levels resulting from the continuous exposure at the cited exposure reference levels. Because VOCs are transient and rapidly eliminated, substantial variation in the blood concentrations would be expected among the individuals both within-and across-days. In the context of the chronic exposure reference values, concern would arise only for the individuals with measured blood values in excess of the screening BE values occurring on a continuous and/or frequent basis. Exposures to VOCs tend to be intermittent in nature and exhibit considerable temporal variation. In children, temporal (intra-individual) variation exceeded inter-individual variation for the blood levels of most the VOCs detected (Sexton et al., 2005 (Sexton et al., , 2006 non-published sources are available (USEPA, 2010), and could be used to derive screening BE values using the steadystate solutions published in Aylward et al., (2010) ; however, such an approach was outside the scope of the current effort. Two VOCs in the NHANES data set (1,3-dichlorobenzene, 2,5-dimethylfuran) were lacking toxicity values for either non-cancer or cancer endpoints. One possible approach for these chemicals would be to identify a toxicity surrogate based upon a chemical with similar structure and mode of action. For example, use of BE values for 1,2-dichlorobenzene (0.7 mg/l; Table 2 ) to assess 1,3-dichlorobenzene, and BE values for furan (0.04 mg/l; Aylward et al., 2010) to assess 2,5-dimethylfuran would suggest that the potential for deleterious non-cancer effects from these chemicals is low.
This assessment includes a consideration of the potential impacts of the presence of multiple VOCs in blood (1) across the routes of exposure by relying upon internal dose-based HQ values; and (2) across chemicals by segregating HQ values by the target organ system of the non-cancer toxicity endpoint used as the basis of the risk assessment derivation. Inherent to this approach is an assumption that the dose of individual components are additive in producing a response at the target tissue. Potential interactions leading to synergism (i.e., greater than additive) or antagonism (i.e., less than additive) were not addressed, nor could the potential contributions to risk from chemicals not measured or evaluated here be addressed. Alternative approaches to cumulative risk assessment include other component-based approaches (including response addition, relative potency factors, and interaction-based HI calculation), relying upon whole mixture's testing (USEPA, 2000 (USEPA, , 2003 , and accounting for interactions via metabolism when analytes compete for the same enzymes. However, based on the fact that the screening endpoint-specific HI values at or near 1 calculated herein are largely driven by a single chemical (benzene for the blood system in smokers; xylene for the neurological system in smokers), further iteration (i.e., beyond the IPCS Tier 0) of the analysis of combined exposures to multiple chemicals, using a more complex and accurate IPCS Tier 1-3 approach for VOCs does not appear to be warranted.
The value of a screening risk assessment is the reduced level of effort and the ability to prioritize which chemicals warrant further investigation, including a more robust risk assessment approach relying on a full BE, exposure pathway investigations, examination of the risk assessment assumptions, and other risk assessment and risk management approaches. The screening approach used here results in valuable perspectives regarding the relative hazards of the VOC compounds examined in the NHANES in the general population. The findings that levels of VOCs in non-smokers are below the cancer and non-cancer regulatory exposure guidance values, using this conservative screening evaluation indicate that additional, more detailed risk assessments for the VOCs included in this analysis are probably not warranted for the general population as a whole, although subpopulations with unusual exposures or other characteristics of interest may warrant further study. For smokers, however, biomonitoring levels for specific smoking-related VOCs approach or exceed the non-cancer and cancer-based regulatory exposure guidance values.
In conclusion, for the small number of VOCs with detectable blood concentrations in the NHANES data set, the potential for deleterious non-cancer effects appears low but is affected by the smoking status of the participants. For non-detected compounds, the analytical sensitivity of the NHANES program was generally sufficient to draw clear conclusions that on a population basis, if exposures are occurring, they are generally resulting in the blood levels that are below levels of concern in the context of current risk assessments. 
